The AMR Accelerator is an IMI Programme that comprises 7 projects with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections.
The AMR Accelerator aims to deliver up to 10 new preclinical candidates and 5 Phase II-ready assets by 2025.
With a wide-ranging series of antibacterial programmes the AMR Accelerator will enhance the overall pipeline of antibiotics to treat infections with M. tuberculosis, nontuberculous mycobacteria (NTM) and Gram-negative bacteria.
The AMR Accelerator is composed of three Pillars:
A Capability Building Network (the COMBINE project) provides coordination and support across the Accelerator, and in addition has scientific goals to improve and standardise the animal models used in AMR research, and optimise clinical trial designs.
The Tuberculosis Drug Development Network (encompassing the ERA4TB project) is working to accelerate the discovery of new combinations of drugs to treat tuberculosis.
The Portfolio Building Networks (the RespiriTB, RespiriNTM, TRIC-TB, GNA NOW and AB-Direct projects) support collaborative efforts to discover, develop and advance new and innovative antibacterial assets.
|The AMR Accelerator has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreements No 853967 I 853989 I 853979 I 853932 I 853800 I 853903 I 853976. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. ERA4TB receives additional support from Global Alliance for TB Drug Development, Bill & Melinda Gates Foundation and University of Dundee.